JPMorgan Chase & Co. Issues Pessimistic Forecast for Clorox (NYSE:CLX) Stock Price

Clorox (NYSE:CLX) had its target price dropped by JPMorgan Chase & Co. from $135.00 to $127.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 5.71% from the company’s previous close.

A number of other brokerages have also recently weighed in on CLX. Wells Fargo & Company dropped their price target on Clorox from $130.00 to $125.00 and set an “equal weight” rating on the stock in a research note on Thursday, September 25th. The Goldman Sachs Group dropped their price target on Clorox from $115.00 to $110.00 and set a “sell” rating on the stock in a research note on Wednesday, October 1st. UBS Group dropped their price target on Clorox from $134.00 to $128.00 and set a “neutral” rating on the stock in a research note on Wednesday. TD Cowen lowered their target price on Clorox from $120.00 to $117.00 and set a “hold” rating on the stock in a research note on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Clorox in a research note on Saturday, September 27th. One analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $131.92.

Clorox Price Performance

Shares of CLX opened at $120.14 on Friday. The firm has a market capitalization of $14.63 billion, a price-to-earnings ratio of 18.43, a price-to-earnings-growth ratio of 0.98 and a beta of 0.52. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. Clorox has a one year low of $116.53 and a one year high of $171.37. The stock’s fifty day moving average is $122.21 and its 200-day moving average is $128.69.

Clorox (NYSE:CLX) last released its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.24 by $0.63. The firm had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.Clorox’s revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities analysts anticipate that Clorox will post 7.15 EPS for the current year.

Insiders Place Their Bets

In related news, COO Eric H. Reynolds sold 15,041 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the completion of the sale, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.57% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Clorox by 1.7% during the second quarter. Vanguard Group Inc. now owns 15,845,496 shares of the company’s stock worth $1,902,569,000 after buying an additional 272,420 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Clorox by 138.3% during the second quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock worth $389,648,000 after buying an additional 1,883,465 shares during the last quarter. Norges Bank bought a new stake in shares of Clorox during the second quarter valued at approximately $190,429,000. Northern Trust Corp increased its position in shares of Clorox by 2.3% during the first quarter. Northern Trust Corp now owns 1,528,920 shares of the company’s stock valued at $225,133,000 after purchasing an additional 34,655 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Clorox by 218.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock valued at $149,983,000 after purchasing an additional 856,873 shares during the period. 78.53% of the stock is currently owned by institutional investors and hedge funds.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.